Velano Vascular has secured $10 million as the initial tranche of a growth financing to fuel commercialization and the launch of new vascular access solutions.

Schaffhausen, Switzerland-based Physeon is trying to bring its Veinplicity device to the U.S. market.

Atellica Solution is a multi analyzer system for in vitro diagnostic testing of clinical specimens.

Point-of-care (POC) testing is a rapidly growing market.

A November 2018 FDA inspection has resulted in a warning letter for Zeller Power Products.

Robotics in medtech are quickly becoming common place as the number of companies in the market continue to grow.

Grail has hit a major milestone as the liquid biopsy company is reporting...

German molecular diagnostics firm Curetis said recently that it will receive €6.5 million ($7.3 million) in gross proceeds under two financing facilities.

NeoGenomics said after the close of the market recently that it has priced its previously announced underwritten public offering of 7 million shares of its common stock at a public offering price of $21.25 per share.

Turning Point Therapeutics and Almac Diagnostic Services recently announced approval by the US Food and Drug Administration of an investigational device exemption for use of an Almac diagnostic assay to determine......

PrediLife said recently that it has signed on the Institut Curie to perform the genetic analysis portion of its MammoRisk breast cancer risk assay.

Qiagen reported after the close of the market recently that its first quarter revenues grew nearly 2 percent year over year as the firm fell short of analysts' topline estimates but beat expectations on the bottom line.

Biocartis announced it has entered into an agreement with AstraZeneca.

Becton Dickinson said today that the US Food and Drug Administration has granted 510(k) clearance for its BD Max enteric viral panel, a molecular diagnostic test for the detection and differentiation of pathogens that cause viral gastroenteritis.

Siemens Healthineers (Erlangen, Germany) has entered into a strategic partnership with Australian integrated healthcare provider Primary Health Care to deploy more than 70 Atellica Solution immunoassay and clinical chemistry analyzers,